Clinical Trials & Research
Search Clinical Trials
|Title||Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection|
|Disease/Condition||Head and Neck Cancer|
|Description||The purpose of this trial is to study the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and HIV infection.|
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving vorinostat together with paclitaxel and carboplatin may kill more tumor cells.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older
* Patient has histologically confirmed solid malignancy meeting 1 of the following criteria:
-Non-small cell lung cancer
-Head and neck squamous cell carcinoma.
- Non-gastroesophageal junction esophageal cancer.
- Solid tumor that is sensitive to carboplatin and/or taxanes including, but not limited to, any of the following (dose-escalation phase only):
-Salivary gland cancer
|Principal Investigator||Missak Haigentz, MD|
|Contact Name||Cherly Baker, RN|
|Current Trial Type||Interventional|
|Montefiore Clinical Trial||No|
|CHAM Clinical Trial||No|